The adjuvanted recombinant nanoparticle-based vaccine GBP510/AS03 shows a clinically acceptable safety profile and immunogenicity results comparable to that of the currently available ChAdOx1-S ...
(RTTNews) - AstraZeneca's (AZN.L, AZN) COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant], formerly AZD1222), has been granted full marketing authorization in the European Union, the British drug ...
In a recent study posted to the medRxiv* pre-print server, researchers evaluated the immunogenicity of booster doses of alum-adjuvanted SCB-2019 vaccine candidate's three formulations. They tested ...
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019. Since then, extensive efforts have been made to develop and evaluate ...
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several new viral variants have emerged, leading to the virus becoming more contagious. However, efficient immune ...
Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of ...
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback